Health Care-Related Economic Burden of the Polycystic Ovary Syndrome during the Reproductive Life Span

    Ricardo Azziz, C. Marín, Lalima Hoq, Enkhe Badamgarav, Paul Y. Song
    Image of study
    TLDR Polycystic ovary syndrome costs the U.S. over $4 billion a year, mainly from treating related health issues.
    The document from 2005 estimates the economic burden of polycystic ovary syndrome (PCOS) in reproductive-aged women in the United States to be over $4 billion annually. The costs are primarily due to the treatment of associated conditions such as type 2 diabetes mellitus (DM), menstrual dysfunction/abnormal uterine bleeding (AUB), infertility, and hirsutism. The study suggests that widespread screening for PCOS could be cost-effective, potentially leading to earlier diagnosis and intervention, and reducing the economic burden. The document emphasizes that the costs calculated are conservative estimates and may be higher due to long-term morbidities associated with PCOS that emerge after the reproductive years.
    View this study on →

    Cited in this study